2022
Discovery of Biomarkers of Resistance to Immune Checkpoint Blockade in NSCLC Using High-Plex Digital Spatial Profiling
Moutafi M, Martinez-Morilla S, Divakar P, Vathiotis I, Gavrielatou N, Aung TN, Yaghoobi V, Fernandez AI, Zugazagoitia J, Herbst R, Schalper KA, Rimm DL. Discovery of Biomarkers of Resistance to Immune Checkpoint Blockade in NSCLC Using High-Plex Digital Spatial Profiling. Journal Of Thoracic Oncology 2022, 17: 991-1001. PMID: 35490853, PMCID: PMC9356986, DOI: 10.1016/j.jtho.2022.04.009.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsICI resistanceDigital spatial profilingICI therapyOverall survivalPretreatment samplesQuantitative immunofluorescenceImmune checkpoint blockadeRole of neutrophilsShorter overall survivalCandidate biomarker proteinsCandidate protein biomarkersCohort validationOperable NSCLCUntreated NSCLCCheckpoint inhibitorsCheckpoint blockadeCD66b expressionAdditional patientsClinical efficacyPoor outcomeDiscovery of biomarkersUnivariate analysisNSCLCPatients
2017
Understanding the Effectiveness of Natural Compound Mixtures in Cancer through Their Molecular Mode of Action
Aung TN, Qu Z, Kortschak RD, Adelson DL. Understanding the Effectiveness of Natural Compound Mixtures in Cancer through Their Molecular Mode of Action. International Journal Of Molecular Sciences 2017, 18: 656. PMID: 28304343, PMCID: PMC5372668, DOI: 10.3390/ijms18030656.Peer-Reviewed Original ResearchConceptsAnti-cancer agentsNatural compound mixturesTherapeutic benefitCancer progressionCancer cellsSynergistic therapeutic benefitsPotential molecular targetsPositive therapeutic benefitsAberrant apoptotic pathwaysClinical efficacyTreatment of cancerAdverse reactionsCancer managementMerit further investigationMultiple specific targetsDrug resistanceCancerGenetic abnormalitiesEffective dosageLimited evidenceMolecular targetsScientific evidenceApoptotic mechanismsFurther investigationProgression